Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)

Published:2017-10-02 Issue:3 Volume:20 Page:520-529
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Rosenstock Julio¹,Frias Juan²,Páll Dénes³,Charbonnel Bernard⁴,Pascu Raluca⁵,Saur Didier⁵,Darekar Amanda⁶,Huyck Susan⁷,Shi Harry⁸,Lauring Brett⁷^ORCID,Terra Steven G.⁹^ORCID

Affiliation:

1. Dallas Diabetes Research Center at Medical City; Dallas Texas

2. National Research Institute; Los Angeles California

3. University of Debrecen; Debrecen Hungary

4. University of Nantes; Nantes France

5. Pfizer; Paris France

6. Pfizer; Tadworth UK

7. Merck & Co., Inc; Kenilworth New Jersey

8. Pfizer Inc; New York New York

9. Pfizer Inc; Andover Massachusetts

Funder

Pfizer

Merck & Co

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13103/fullpdf

Reference29 articles.

1. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis;Shyangdan;BMJ Open,2016

2. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis;Zaccardi;Diabetes Obes Metab,2016

3. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors;Mascitti;J Med Chem,2011

4. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin;Amin;Diabetes Obes Metab,2015

5. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension;Amin;Diabetes Obes Metab,2015

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of serum level of furin enzyme activity, fatty acid binding protein-4 (FABP-4) and insulin resistance in patients with pre-diabetes and newly diagnosed type 2 diabetes mellitus;Anaesthesia, Pain & Intensive Care;2024-08-09

2. Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis;International Journal of Molecular Sciences;2024-07-22

3. SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials;Journal of Cardiovascular Electrophysiology;2024-06-28

4. Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors;International Journal of Molecular Sciences;2024-06-25

5. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus;Diabetology & Metabolic Syndrome;2024-05-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3